BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma

March 26, 2021 Auto Bot BMS, Clinical Trials, Metastatic, patients, Report, results 0

Shots:

  • The P-II/III RELATIVITY-047 (CA224-047) study involves assessing the FD combination of relatlimab (160 mg) + Opdivo (480mg) vs Opdivo (480mg, IV, q4w) alone in 714 patients in a ratio (1:1) with previously untreated metastatic or unresectable melanoma
  • The study met its 1EPs of the PFS while the follow-up for 2EPs of OS and ORR is ongoing. The combination was well-tolerated
  • Relatlimab is a fully human LAG3-specific Ab, currently being evaluated in clinical trials in combination with other agents in a variety of tumor types

Click here ­to­ read full press release/ article | Ref: BusinessWire | Image: Fierce Pharma

The post BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma first appeared on PharmaShots.